0OB3 Stock Chart & Stats
€2.10
€0.05(2.18%)
At close: 4:00 PM EDT
€2.10
€0.05(2.18%)
Day’s Range― - ―
52-Week Range€2.03 - €5.34
Previous CloseN/A
Volume143.00
Average Volume (3M)106.96K
Market Cap
€582.60M
Enterprise Value€516.36
Total Cash (Recent Filing)€121.53M
Total Debt (Recent Filing)€210.23M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 12, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding189,771,240
10 Day Avg. Volume86,772
30 Day Avg. Volume106,960
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€151.53M
Bulls Say, Bears Say
Bulls Say
Late-stage Lyme Vaccine OpportunityThe Lyme program could materially expand Valneva’s addressable market if approved. Its late-stage status, strong reported efficacy and Pfizer’s regulatory progress provide a credible route to a differentiated commercial product.
Restructuring And Operating Cost DisciplineWorkforce reductions, project reprioritization and lower operating expenses can improve the company’s cost base beyond the current period. This may strengthen operating leverage if vaccine sales stabilize or pipeline programs advance.
Established Commercial Vaccine FranchiseThe marketed portfolio provides recurring revenue and commercial infrastructure while pipeline assets develop. Material sales from IXIARO, DUKORAL and IXCHIQ offer an operating base that can support future launches and partnerships.
Bears Say
Deepening Losses And Weak ProfitabilityLarge operating and EBITDA losses indicate that current product revenue does not yet cover manufacturing and development costs. Persistent losses reduce financial flexibility and make successful cost reduction and pipeline execution essential.
Declining Revenue And Product DemandBroad declines across total revenue and product sales weaken the funding base for research and commercialization. Lower IXIARO, DUKORAL and IXCHIQ sales also raise questions about sustained demand and the portfolio’s near-term operating scale.
Cash Burn And Rising Financial LeverageOngoing cash consumption alongside a shrinking equity cushion increases reliance on external funding. Higher leverage can constrain investment in the pipeline and heighten financing risk if losses continue or regulatory milestones are delayed.
Valneva News
0OB3 FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest share price was €2.03 and its highest was €5.34 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €582.60M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Nov 12, 2026 which is in 85 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Aug 13, 2026. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of -€0.089 by -€0.081.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.07.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.17 in its last earnings report, missing expectations of -€0.089. Following the earnings report the stock price went down -1.709%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in GB:0OB3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.